Lilit Garibyan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lilit Garibyan has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
R. Rox Anderson
Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, USA
7 shared publicationsSara Moradi Tuchayi
Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, USA
7 shared publicationsYing Wang
Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, USA
6 shared publications- Merete Haedersdal
Department of Dermatology Copenhagen University Hospital ‐ Bispebjerg Copenhagen Denmark
4 shared publications Anat Stemmer-Rachamimov
Massachusetts General Hospital, Department of Dermatology, Harvard Medical School, Boston, USA
3 shared publications- Dominique du Crest
SkinAid SAS Paris France
3 shared publications
Latest Publications
- Open Access
- 9 April 2026
- Published by Wiley in JEADV Clinical Practice
Startups Driving Artificial Intelligence Into Clinical Dermatology
Artificial intelligence (AI) is rapidly transitioning from innovation to routine clinical application in dermatology. This review examines how AI‐enabled technologies are being developed and integrated across diverse clinical purposes and workflows. Using a structured assessment template, we analyzed international initiatives and industry‐led innovations to identify the clinical gaps addressed, underlying technologies, use cases, and real‐world implementation experiences. The resulting profiles highlight a broad spectrum of AI‐driven and enabled applications, including wearable sensors with haptic feedback for objective symptom monitoring; patient‐initiated teledermatology platforms that enhance access to specialist care; non‐invasive diagnostic tools employing impedance spectroscopy; autonomous triage systems for dermoscopic lesions; and sensors that combine intrinsic skin biomarkers with exposome analytics. Collectively, these technologies illustrate a shift toward generating objective, reproducible data that complement clinical assessment, facilitating earlier detection, streamlined referrals, and longitudinal, patient‐centred care. While validation studies are encouraging, regulatory and reimbursement pathways, along with limited data diversity, are current hurdles to a more large‐scale adoption. By synthesizing insights from these technological approaches, this review aims to provide dermatologists with a pragmatic overview of AI‐driven health technologies as emerging, evidence‐based, commercial initiatives that may shape the future of dermatologic care.
- 9 April 2026
- Published by Wiley in JEADV Clinical Practice
Open AccessStartups Driving Artificial Intelligence Into Clinical Dermatology
Artificial intelligence (AI) is rapidly transitioning from innovation to routine clinical application in dermatology. This review examines how AI‐enabled technologies are being developed and integrated across diverse clinical purposes and workflows. Using a structured assessment template, we analyzed international initiatives and industry‐led innovations to identify the clinical gaps addressed, underlying technologies, use cases, and real‐world implementation experiences. The resulting profiles highlight a broad spectrum of AI‐driven and enabled applications, including wearable sensors with haptic feedback for objective symptom monitoring; patient‐initiated teledermatology platforms that enhance access to specialist care; non‐invasive diagnostic tools employing impedance spectroscopy; autonomous triage systems for dermoscopic lesions; and sensors that combine intrinsic skin biomarkers with exposome analytics. Collectively, these technologies illustrate a shift toward generating objective, reproducible data that complement clinical assessment, facilitating earlier detection, streamlined referrals, and longitudinal, patient‐centred care. While validation studies are encouraging, regulatory and reimbursement pathways, along with limited data diversity, are current hurdles to a more large‐scale adoption. By synthesizing insights from these technological approaches, this review aims to provide dermatologists with a pragmatic overview of AI‐driven health technologies as emerging, evidence‐based, commercial initiatives that may shape the future of dermatologic care.
- Open Access
- 10 April 2025
- Published by Elsevier in JID Innovations
- Vol. 5 (4) , 100371
Skin & Digital: The 2024 Startups
- 10 April 2025
- Published by Elsevier in JID Innovations
- Vol. 5 (4) , 100371
Open AccessSkin & Digital: The 2024 Startups
- Open Access
- 24 March 2025
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 9 (12)
Molecular detection of Tropheryma whipplei DNA: a crucial tool for diagnosing Whipple’s disease in the brain. Illustrative case
BACKGROUND: Whipple’s disease is a rare chronic infectious disorder caused by the bacterium Tropheryma whipplei. It commonly involves the small intestine and presents with chronic diarrhea, abdominal pain, weight loss, enlarged lymph nodes, and migratory polyarthralgia, with involvement of the CNS. OBSERVATIONS: The authors describe the case of a 69-year-old male who presented with arthritis on immunomodulatory treatment, weight loss, confusion, worsening memory, and right-sided weakness. MRI of the brain revealed a 2.4-cm enhancing mass in the left lentiform nucleus. A stereotactic biopsy was performed, with pathology demonstrating granulomatous inflammation with reactive astrocytes. Broad-range polymerase chain reaction and next-generation sequencing of the tissue detected T. whipplei DNA. Intravenous ceftriaxone yielded no clinical improvement. LESSONS: Whipple’s disease should be considered in an immunosuppressed patient presenting with progressive cognitive decline, weight loss, and imaging findings that are atypical for a neoplasm . Whipple’s disease can be diagnosed by histological identification of the organism or by the presence of foamy macrophages containing gram-positive bacilli in the biopsy of the small intestine or affected tissues. Its diagnosis can be challenging as T. whipplei grows inconsistently in culture and can rapidly become undetectable with antibiotic therapy. Molecular detection might be required to improve diagnostic accuracy. https://thejns.org/doi/10.3171/CASE24687
- 24 March 2025
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 9 (12)
Open AccessMolecular detection of Tropheryma whipplei DNA: a crucial tool for diagnosing Whipple’s disease in the brain. Illustrative case
BACKGROUND: Whipple’s disease is a rare chronic infectious disorder caused by the bacterium Tropheryma whipplei. It commonly involves the small intestine and presents with chronic diarrhea, abdominal pain, weight loss, enlarged lymph nodes, and migratory polyarthralgia, with involvement of the CNS. OBSERVATIONS: The authors describe the case of a 69-year-old male who presented with arthritis on immunomodulatory treatment, weight loss, confusion, worsening memory, and right-sided weakness. MRI of the brain revealed a 2.4-cm enhancing mass in the left lentiform nucleus. A stereotactic biopsy was performed, with pathology demonstrating granulomatous inflammation with reactive astrocytes. Broad-range polymerase chain reaction and next-generation sequencing of the tissue detected T. whipplei DNA. Intravenous ceftriaxone yielded no clinical improvement. LESSONS: Whipple’s disease should be considered in an immunosuppressed patient presenting with progressive cognitive decline, weight loss, and imaging findings that are atypical for a neoplasm . Whipple’s disease can be diagnosed by histological identification of the organism or by the presence of foamy macrophages containing gram-positive bacilli in the biopsy of the small intestine or affected tissues. Its diagnosis can be challenging as T. whipplei grows inconsistently in culture and can rapidly become undetectable with antibiotic therapy. Molecular detection might be required to improve diagnostic accuracy. https://thejns.org/doi/10.3171/CASE24687
- 19 December 2024
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 57 (1) , 101-111
Cutaneous Immune Responses to Ablative Fractional Laser, Heat‐ and Cold‐Based Dermatological Procedures
Objective: Physical treatment modalities, such as ablative fractional laser (AFL), electrocautery, and cryotherapy, are extensively used in the field of dermatology. This study aimed to characterize the short‐term innate and adaptive immune responses induced by AFL compared with heat‐ and cold‐based procedures.Materials and Methods: Innate (CD11b+Ly6G+ neutrophils) and adaptive (CD8+CD3+ T cells) immune cell infiltration and histopathological changes were examined in murine skin on Days 1 and 7, following AFL, monopolar‐electrocautery (RF), thermocautery, and cryotherapy. Interventions were standardized to reach the reticular dermis. Clinical skin reactions were photo‐documented daily. As a comparator, the adaptive immune response was examined in murine basal cell carcinomas (BCC) on Day 7 after AFL exposure.Results: Baseline histopathology confirmed immediate deep dermal tissue impact by all procedures. Immune cell dynamics varied across treatments throughout the progression of clinical and histopathological responses. On Day 1, AFL and heat‐based procedures triggered an innate immune response, characterized by CD11b+Ly6G+ neutrophil cell infiltration that correlated with histopathological findings and immediate onset of clinical skin reactions. In addition, heat‐based procedures led to an increase in overall dermal CD45+ cells (Day 1), which continued to rise for AFL and RF‐electrocautery at Day 7 posttreatment. On the contrary, cryotherapy did not induce immediate (Day 1) innate immune responses, but instead a delayed increase in neutrophil and CD45+ cell infiltration (Day 7), which coincided with the late onset of clinical reaction. CD3+ T cells and CD8+CD3+ T cells demonstrated a similar pattern, with an increase observed for heat‐based procedures on Day 1 and a delayed increase for cryotherapy on Day 7. Distinctive for AFL‐treated skin, the level of dermal CD3+ T cells increased over time, significant by Day 7, and AFL‐treated mouse BCCs responded with increased CD8+ T cell infiltration at Day 7 posttreatment.Conclusion: Heat‐ and cold‐based procedures developed distinct cutaneous immune responses, with cryotherapy resulting in a delayed response compared to immediate immune responses from heat‐based procedures. The substantial T cell response induced by AFL in the skin and BCC tumors indicates a potential for AFL as an adjuvant in immunotherapeutic treatments of keratinocyte cancers.
- 19 December 2024
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 57 (1) , 101-111
Cutaneous Immune Responses to Ablative Fractional Laser, Heat‐ and Cold‐Based Dermatological Procedures
Objective: Physical treatment modalities, such as ablative fractional laser (AFL), electrocautery, and cryotherapy, are extensively used in the field of dermatology. This study aimed to characterize the short‐term innate and adaptive immune responses induced by AFL compared with heat‐ and cold‐based procedures.Materials and Methods: Innate (CD11b+Ly6G+ neutrophils) and adaptive (CD8+CD3+ T cells) immune cell infiltration and histopathological changes were examined in murine skin on Days 1 and 7, following AFL, monopolar‐electrocautery (RF), thermocautery, and cryotherapy. Interventions were standardized to reach the reticular dermis. Clinical skin reactions were photo‐documented daily. As a comparator, the adaptive immune response was examined in murine basal cell carcinomas (BCC) on Day 7 after AFL exposure.Results: Baseline histopathology confirmed immediate deep dermal tissue impact by all procedures. Immune cell dynamics varied across treatments throughout the progression of clinical and histopathological responses. On Day 1, AFL and heat‐based procedures triggered an innate immune response, characterized by CD11b+Ly6G+ neutrophil cell infiltration that correlated with histopathological findings and immediate onset of clinical skin reactions. In addition, heat‐based procedures led to an increase in overall dermal CD45+ cells (Day 1), which continued to rise for AFL and RF‐electrocautery at Day 7 posttreatment. On the contrary, cryotherapy did not induce immediate (Day 1) innate immune responses, but instead a delayed increase in neutrophil and CD45+ cell infiltration (Day 7), which coincided with the late onset of clinical reaction. CD3+ T cells and CD8+CD3+ T cells demonstrated a similar pattern, with an increase observed for heat‐based procedures on Day 1 and a delayed increase for cryotherapy on Day 7. Distinctive for AFL‐treated skin, the level of dermal CD3+ T cells increased over time, significant by Day 7, and AFL‐treated mouse BCCs responded with increased CD8+ T cell infiltration at Day 7 posttreatment.Conclusion: Heat‐ and cold‐based procedures developed distinct cutaneous immune responses, with cryotherapy resulting in a delayed response compared to immediate immune responses from heat‐based procedures. The substantial T cell response induced by AFL in the skin and BCC tumors indicates a potential for AFL as an adjuvant in immunotherapeutic treatments of keratinocyte cancers.
- Open Access
- 19 September 2024
- Published by Elsevier in JID Innovations
- Vol. 5 (1) , 100316
Skin & Digital: The 2023 Startups/Innovators
- 19 September 2024
- Published by Elsevier in JID Innovations
- Vol. 5 (1) , 100316
Open AccessSkin & Digital: The 2023 Startups/Innovators
- Open Access
- 28 September 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-9
Selective reduction of visceral adipose tissue with injectable ice slurry
Reduction in visceral adipose tissue (VAT) mass reduces body weight and metabolic disease risk in obese patients. However surgical removal of VAT is highly invasive and thus not clinically feasible. We developed an injectable ice slurry for selective reduction of adipose tissue through cryolipolysis. The aim of this study was to investigate safety, feasibility and mechanism of ice slurry-induced cryolipolysis of VAT. Perigonadal VAT in diet-induced obese mice and rats was subjected to slurry or sham treatment. Body weight and blood chemistry were monitored for 56 days post-treatment. Histological analysis and molecular studies were performed to elucidate mechanisms of fat reduction. Treatment of VAT was well tolerated in all animals. Slurry induced adipocyte cell death via selective cryolipolysis; significant weight loss was noted at day 21 post-treatment. RNA sequencing from treated VAT samples showed increased expression of genes involved in inflammation, immune response, collagen biosynthesis and wound healing, and decreased expression of adipokines. This study demonstrates that slurry treatment is safe and effective in inducing cryolipolysis of VAT and subsequent weight loss in mice. Ice slurry is promising as a minimally-invasive treatment to reduce visceral adipose tissue.
- 28 September 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-9
Open AccessSelective reduction of visceral adipose tissue with injectable ice slurry
Reduction in visceral adipose tissue (VAT) mass reduces body weight and metabolic disease risk in obese patients. However surgical removal of VAT is highly invasive and thus not clinically feasible. We developed an injectable ice slurry for selective reduction of adipose tissue through cryolipolysis. The aim of this study was to investigate safety, feasibility and mechanism of ice slurry-induced cryolipolysis of VAT. Perigonadal VAT in diet-induced obese mice and rats was subjected to slurry or sham treatment. Body weight and blood chemistry were monitored for 56 days post-treatment. Histological analysis and molecular studies were performed to elucidate mechanisms of fat reduction. Treatment of VAT was well tolerated in all animals. Slurry induced adipocyte cell death via selective cryolipolysis; significant weight loss was noted at day 21 post-treatment. RNA sequencing from treated VAT samples showed increased expression of genes involved in inflammation, immune response, collagen biosynthesis and wound healing, and decreased expression of adipokines. This study demonstrates that slurry treatment is safe and effective in inducing cryolipolysis of VAT and subsequent weight loss in mice. Ice slurry is promising as a minimally-invasive treatment to reduce visceral adipose tissue.
- Open Access
- 11 April 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (8) , 1406-1411
Sunscreens: Misconceptions and Misinformation
- 11 April 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (8) , 1406-1411
Open AccessSunscreens: Misconceptions and Misinformation
- Open Access
- 18 November 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-6
Fast-acting and injectable cryoneurolysis device
Cryoneurolysis is an opioid-sparing therapy for long-lasting and reversible reduction of pain. We developed a nerve-selective method for cryoneurolysis by local injection of ice-slurry (− 5 to − 6 °C) that induced decrease in nocifensive response starting from about a week after treatment and lasting up to 8 weeks. In this study, we test the hypothesis that injection of colder slurry leads to faster onset of analgesia. Colder slurry (− 9ºC) was injected around the rat sciatic nerve to induce cryoneurolysis. Hematoxylin and Eosin (H&E) staining was used to examine histologic effects on surrounding tissues. Coherent anti-Stokes Raman scattering (CARS) microscopy was used to study effects on myelin sheaths. Functional tests were used to assess changes in sensory and motor function in the treated hind paw. No inflammation or scarring was detected in surrounding skin and muscle tissues at day 7 post slurry injection. Functional tests showed rapid onset reduction in mechanical pain sensitivity starting from day 1 and lasting up to day 98. CARS imaging demonstrated disintegration of myelin sheaths post treatment followed by complete recovery of nerve structure by day 140. In this study we showed that colder slurry (− 9 °C) produces more rapid onset and longer duration of analgesia, while remaining nerve-selective
- 18 November 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-6
Open AccessFast-acting and injectable cryoneurolysis device
Cryoneurolysis is an opioid-sparing therapy for long-lasting and reversible reduction of pain. We developed a nerve-selective method for cryoneurolysis by local injection of ice-slurry (− 5 to − 6 °C) that induced decrease in nocifensive response starting from about a week after treatment and lasting up to 8 weeks. In this study, we test the hypothesis that injection of colder slurry leads to faster onset of analgesia. Colder slurry (− 9ºC) was injected around the rat sciatic nerve to induce cryoneurolysis. Hematoxylin and Eosin (H&E) staining was used to examine histologic effects on surrounding tissues. Coherent anti-Stokes Raman scattering (CARS) microscopy was used to study effects on myelin sheaths. Functional tests were used to assess changes in sensory and motor function in the treated hind paw. No inflammation or scarring was detected in surrounding skin and muscle tissues at day 7 post slurry injection. Functional tests showed rapid onset reduction in mechanical pain sensitivity starting from day 1 and lasting up to day 98. CARS imaging demonstrated disintegration of myelin sheaths post treatment followed by complete recovery of nerve structure by day 140. In this study we showed that colder slurry (− 9 °C) produces more rapid onset and longer duration of analgesia, while remaining nerve-selective
- 19 September 2022
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 315 (3) , 513-519
Innovating on innovation training with the Virtual Magic Wand (VMW) program: a qualitative study
To identify and solve unmet needs and bring new therapies to patients, clinicians at all levels must engage in innovation. The Magic Wand Initiative, a program based at Massachusetts General Hospital—Wellman Center for Photomedicine, created a 10-months course called the Virtual Magic Wand (VMW) program that is a curriculum that teaches the biomedical innovation pathway to dermatologists and engages them in this creative process. This study aims to identify the impact of the VMW program on participants and consider the potential benefits of an innovation curriculum. The authors conducted semi-structured interviews in which alumni of the VMW program were asked about their experiences with innovation before, during, and after the program. Using grounded theory methodology, data were analyzed using deductive coding methods. The most cited benefit of the program was the opportunity to network (n = 12, 100%)—specifically, the mentorship opportunities (n = 10, 83%) and specialty-specific peer groups (n = 9, 75%). Other benefits included a change in mindset regarding their clinical work (n = 11, 92%) and learning the process of innovation (83%). Among barriers, lack of time (n = 7, 58%), knowledge (n = 6, 50%), and resources (n = 5, 42%), were the most mentioned. All alumni interviewed have stayed engaged in the field of biomedical innovation after their completion of the VMW program. These findings show that the VMW program positively impacted the lives and careers of participants. This study identified some of the systemic reasons that deter physicians from regularly engaging in innovation and provides guidance for how to design other innovation programs and further support the advancement of medicine.
- 19 September 2022
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 315 (3) , 513-519
Innovating on innovation training with the Virtual Magic Wand (VMW) program: a qualitative study
To identify and solve unmet needs and bring new therapies to patients, clinicians at all levels must engage in innovation. The Magic Wand Initiative, a program based at Massachusetts General Hospital—Wellman Center for Photomedicine, created a 10-months course called the Virtual Magic Wand (VMW) program that is a curriculum that teaches the biomedical innovation pathway to dermatologists and engages them in this creative process. This study aims to identify the impact of the VMW program on participants and consider the potential benefits of an innovation curriculum. The authors conducted semi-structured interviews in which alumni of the VMW program were asked about their experiences with innovation before, during, and after the program. Using grounded theory methodology, data were analyzed using deductive coding methods. The most cited benefit of the program was the opportunity to network (n = 12, 100%)—specifically, the mentorship opportunities (n = 10, 83%) and specialty-specific peer groups (n = 9, 75%). Other benefits included a change in mindset regarding their clinical work (n = 11, 92%) and learning the process of innovation (83%). Among barriers, lack of time (n = 7, 58%), knowledge (n = 6, 50%), and resources (n = 5, 42%), were the most mentioned. All alumni interviewed have stayed engaged in the field of biomedical innovation after their completion of the VMW program. These findings show that the VMW program positively impacted the lives and careers of participants. This study identified some of the systemic reasons that deter physicians from regularly engaging in innovation and provides guidance for how to design other innovation programs and further support the advancement of medicine.
- Open Access
- 14 September 2022
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 15, 2905-2910
Full Recovery after Multiple Treatments with Injectable Ice Slurry
Background: Cryoneurolysis uses tissue cooling as an opioid-sparing, long-lasting treatment for peripheral nerve pain. A nerve-selective method for cryoneurolysis by local injection of ice-slurry was developed to allow cryoneurolysis to be performed with a standard needle and syringe, similar to peripheral nerve blocks. Since the treatment of patients with chronic pain may require repeated injections, we investigated the safety and tolerance of repeated treatments in a rat model. Methods: Three repeated ice-slurry treatments, given 6 weeks apart were performed around the rat sciatic nerve. Nerve and surrounding tissues were collected up to 4 months after the third treatment for analysis. Coherent anti-Stokes Raman scattering (CARS) microscopy was used to study effects on myelin sheaths and axon structure. Immunofluorescence (IF) staining was used to study effects on axon density. Hematoxylin and Eosin (H&E) staining was used to examine histologic effects on sciatic nerve and surrounding tissue. Results: Histologic and CARS image analysis of nerve tissue collected months after three injections demonstrated recovery of nerve structure, myelin organization and axon density to baseline levels, without any residual inflammation, scarring or neuroma formation. No inflammation or scarring was detected in surrounding skin and muscle tissues. Conclusion: Repeated ice-slurry injections cause temporary, nerve-selective and reversible changes in the peripheral nerve. There was no histologic damage to surrounding skin and muscle tissues. Repeated treatments with injectable ice-slurry for cryoneurolysis appear to be safe and well tolerated. Clinical studies for patients with chronic pain are warranted.
- 14 September 2022
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 15, 2905-2910
Open AccessFull Recovery after Multiple Treatments with Injectable Ice Slurry
Background: Cryoneurolysis uses tissue cooling as an opioid-sparing, long-lasting treatment for peripheral nerve pain. A nerve-selective method for cryoneurolysis by local injection of ice-slurry was developed to allow cryoneurolysis to be performed with a standard needle and syringe, similar to peripheral nerve blocks. Since the treatment of patients with chronic pain may require repeated injections, we investigated the safety and tolerance of repeated treatments in a rat model. Methods: Three repeated ice-slurry treatments, given 6 weeks apart were performed around the rat sciatic nerve. Nerve and surrounding tissues were collected up to 4 months after the third treatment for analysis. Coherent anti-Stokes Raman scattering (CARS) microscopy was used to study effects on myelin sheaths and axon structure. Immunofluorescence (IF) staining was used to study effects on axon density. Hematoxylin and Eosin (H&E) staining was used to examine histologic effects on sciatic nerve and surrounding tissue. Results: Histologic and CARS image analysis of nerve tissue collected months after three injections demonstrated recovery of nerve structure, myelin organization and axon density to baseline levels, without any residual inflammation, scarring or neuroma formation. No inflammation or scarring was detected in surrounding skin and muscle tissues. Conclusion: Repeated ice-slurry injections cause temporary, nerve-selective and reversible changes in the peripheral nerve. There was no histologic damage to surrounding skin and muscle tissues. Repeated treatments with injectable ice-slurry for cryoneurolysis appear to be safe and well tolerated. Clinical studies for patients with chronic pain are warranted.